Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NAFLD Activity Score(NAS) ≥ 3 (Biopsy-proven)~Exclusion Criteria:~* Alcohol consumption \> 20g/day~* Type 1 diabetes or poorly controlled diabetes mellitus (HbA1c ≥ 9%)~* Evidence of other chronic liver disease (e.g. HBsAg positive, anti-HCV positive, autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency and etc.)~* ALT, AST \> 5X the upper limit of normal~* Serum creatinine ≥ 2mg/dl~* Fibrosis score ≥ 3 according to the NASH CRN fibrosis staging system~* NQO1 T/T type~* Weight loss of more than 5kg within 6 months~* Bariatric surgery within 6 months~* Known alcohol or any other drug abuse in the last five years~* Insulin sensitizers, hepatoprotective agents, anti-oxidants, lipid-lowering agents, drugs induced fatty liver within 1 month

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MB12066 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).